Home
/
Actinium Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Actinium Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Actinium Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$90.0K
Nov 14, 2025
Q3
2023
Sep 30, 2022
$45.0K
Nov 2, 2023
Q2
2023
Jun 30, 2022
$45.0K
Aug 14, 2023
Q1
2023
Mar 31, 2022
$940.0K
May 15, 2023
Q3
2022
Sep 30, 2021
$233.0K
Nov 14, 2022
Q2
2022
Jun 30, 2021
$266.0K
Aug 12, 2022
Q1
2022
Mar 31, 2021
$622.0K
May 13, 2022
Q3
2012
Sep 30, 2012
$0
Nov 14, 2012
Q2
2012
Jun 30, 2012
$0
Aug 29, 2012
Q3
2012
Sep 30, 2011
$0
Nov 14, 2012
Q2
2012
Jun 30, 2011
$0
Aug 29, 2012
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2012
Sep 30, 2012
$0
Nov 14, 2012
Q2
2012
Jun 30, 2012
$0
Aug 29, 2012
Q1
2012
Mar 31, 2012
$0
Apr 23, 2012
Q1
2012
Dec 31, 2011
$0
Apr 23, 2012
Q3
2012
Sep 30, 2011
$0
Nov 14, 2012
Q2
2011
Jun 30, 2011
$0
Aug 12, 2011
Q3
2011
Sep 30, 2010
$0
Nov 14, 2011
Q2
2011
Jun 30, 2010
$0
Aug 12, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.13M)
Nov 14, 2025
Q3
2025
Jun 30, 2025
($6.88M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($6.88M)
Aug 8, 2025
Q2
2025
Mar 31, 2025
($15.94M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($15.94M)
May 9, 2025
Q3
2025
Mar 31, 2025
($15.94M)
Nov 14, 2025
Q3
2025
Sep 30, 2024
($11.57M)
Nov 14, 2025
Q3
2025
Jun 30, 2024
($11.35M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($11.35M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($8.67M)
May 9, 2025
Q2
2025
Mar 31, 2024
($8.67M)
Aug 8, 2025
Q3
2025
Mar 31, 2024
($8.67M)
Nov 14, 2025
Q3
2024
Sep 30, 2023
($13.28M)
Nov 14, 2024
Q3
2024
Jun 30, 2023
($15.18M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($15.18M)
Aug 5, 2024
Q2
2024
Mar 31, 2023
($11.04M)
Aug 5, 2024
Q3
2024
Mar 31, 2023
($11.04M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($11.04M)
Apr 26, 2024
Q3
2023
Sep 30, 2022
($9.47M)
Nov 2, 2023
Q3
2023
Jun 30, 2022
($7.77M)
Nov 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.69M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($7.50M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($16.64M)
May 9, 2025
Q3
2025
Sep 30, 2024
($12.60M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($12.42M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
($9.60M)
May 9, 2025
Q3
2024
Sep 30, 2023
($14.35M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($15.64M)
Aug 5, 2024
Q1
2024
Mar 31, 2023
($11.58M)
Apr 26, 2024
Q3
2023
Sep 30, 2022
($9.80M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($7.85M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($5.16M)
May 15, 2023
Q3
2022
Sep 30, 2021
($6.47M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($5.08M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($5.37M)
May 13, 2022
Q3
2021
Sep 30, 2020
($5.61M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($4.66M)
Jul 30, 2021
Q1
2021
Mar 31, 2020
($5.68M)
May 14, 2021
Q3
2020
Sep 30, 2019
($6.65M)
Oct 23, 2020
Q2
2020
Jun 30, 2019
($5.09M)
Aug 14, 2020